FINWIRES · TerminalLIVE
FINWIRES

Beijing Shougang LanzaTech Nets HK$486 Million in Hong Kong IPO Ahead of Debut

By

Beijing Shougang LanzaTech Technology (HKG:2553) raised HK$486.5 million in net proceeds from its initial public offering in Hong Kong.

The final offer price was set at HK$14.60 per H-share, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.

The China-based carbon capture, utilization, and storage technology company offered 40 million H-shares in the global offering.

The Hong Kong public offer was 1,421.54 times subscribed, with a final allocation of 6 million shares, representing 15% of the total offering.

The international offering was 0.95 times subscribed, with a final allocation of 34 million shares, or 85% of the total offering.

Beijing Shougang LanzaTech Technology is set to debut on the Hong Kong bourse on Wednesday, June 3.

Related Articles

Asia

Tata Motors Passenger Vehicles' Total Sales Rise 42% in May

Tata Motors Passenger Vehicles' (NSE:TMPV, BOM:500570) total sales rose 42% to 59,790 units in May, against 42,040 units sold a year ago, according to a Monday filing to the Indian bourses.Total domestic sales in May also grew 42% to 59,090 units from 41,557 units a year earlier, the filing said.Of the total, electric vehicle sales jumped 85% year-on-year to 10,517 units from 5,685 units.

BOM:500570NSE:TMPV
Asia

Dian Tou Energy Acquires Baiyinhua Coal & Power for 11.1 Billion Yuan; Shares Down 4%

Inner Mongolia Dian Tou Energy (SHE:002128) fully acquired Baiyinhua Coal & Power for 11.1 billion yuan, according to a Tuesday disclosure on the Shenzhen bourse.The acquisition was made through share placement and capital injection.The company raised 4.50 billion yuan as part of the acquisition funds.The Chinese coal products maker's shares dropped 4% during the morning trade.

SHE:002128
Asia

Formosa Pharmaceuticals Gets Taiwan's Health Ministry for Pain Relief Drug; Shares Rise 3%

Formosa Pharmaceuticals (TPE:6838) received approval from Taiwan's Ministry of Health and Welfare for a drug to treat inflammation and pain following ocular surgery, according to a Monday Taiwan Exchange filing.Shares gained about 3% in Tuesday's late morning trade.The drug dubbed APP13007, is marketed as BYQLOVI Ophthalmic Suspension 0.05%.Financial details and accumulated development costs were not disclosed.

TPE:6838